Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $62.78 Consensus Target Price from Analysts

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received an average rating of “Moderate Buy” from the ten analysts that are covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $62.78.

Several brokerages have recently issued reports on HALO. Wells Fargo & Company reduced their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday. Benchmark reaffirmed a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Finally, Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $60.15 on Tuesday. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The business’s 50-day simple moving average is $55.20 and its two-hundred day simple moving average is $54.74. The stock has a market cap of $7.41 billion, a PE ratio of 17.54, a P/E/G ratio of 0.42 and a beta of 1.25. Halozyme Therapeutics has a 52 week low of $37.73 and a 52 week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. As a group, analysts forecast that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now owns 38,611 shares of the company’s stock, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 31,697 shares of company stock valued at $1,754,451 over the last ninety days. 2.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $10,032,000. Heck Capital Advisors LLC purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $29,000. Armis Advisers LLC purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $295,000. GF Fund Management CO. LTD. purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $128,000. Finally, Novem Group purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $841,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.